A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 4, 2010, Pages 631-636

  Tumlin, James ^a   Goldman, Jesse ^b   Spiegel, David M ^c   Roer, David ^d   Ntoso, K Adu ^e   Blaney, Martha ^f   Jacobs, Joan ^f   Gillespie, Barbara S ^g   Begelman, Susan M ^f  

^a UNIVERSITY OF TENNESSEE AT CHATTANOOGA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Nephrology and Hypertension Associates   (United States)

^e PENNSYLVANIA HOSPITAL   (United States)

^f GENENTECH INC   (United States)

^g IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TENECTEPLASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD FLOW VELOCITY; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIALYSIS CATHETER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GINGIVA BLEEDING; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BLOOD FLOW VELOCITY; CATHETERIZATION, CENTRAL VENOUS; CATHETERIZATION, PERIPHERAL; CATHETERS, INDWELLING; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; RENAL DIALYSIS; THROMBOSIS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 77950933169     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06520909     Document Type: Article

References (32)

1. National Kidney Foundation: Clinical practice guidelines for vascular access. Am J Kidney Dis 48[Suppl 1]: S248-S273, 2006 (Pubitemid 43928200)
2. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7: 523-535, 1996
3. Nassar GM, Ayus JC: Infectious complications of the hemodialysis access. Kidney Int 60: 1-13, 2001
4. U.S. Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008
5. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 1: 305-316, 2002 (Pubitemid 34075158)
6. U.S. Department of Health and Human Services. Centers for Medicare and Medicaid Services: 2007 Annual Report: End Stage Renal Disease (ESRD) Clinical Performance Measures Project. Baltimore, MD, Department of Health and Human Services, Centers for Medicare and Medicaid Services, Office of Clinical Standards and Quality, 2007, pp 1-68
7. Kakkos SK, Haddad GK, Haddad RK, Scully MM: Effectiveness of a new tunneled catheter in preventing catheter malfunction: A comparative study. J Vasc Interv Radiol 19: 1018-1026, 2008
8. Develter W, De Cubber A, Van BW, Vanholder R, Lameire N: Survival and complications of indwelling venous catheters for permanent use in hemodialysis patients. Artif Organs 29: 399-405, 2005 (Pubitemid 41632982)
9. Lee T, Barker J, Allon M: Tunneled catheters in hemodialysis patients: Reasons and subsequent outcomes. Am J Kidney Dis 46: 501-508, 2005 (Pubitemid 41208186)
10. Bamgbola OF, del Rio M, Kaskel FJ, Flynn JT: Recombinant tissue plasminogen activator infusion for hemodialysis catheter clearance. Pediatr Nephrol 20: 989-993, 2005 (Pubitemid 40909274)
11. Castner D: The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters. Nephrol Nurs J 28: 403-410, 2001
12. Daeihagh P, Jordan J, Chen J, Rocco M: Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 36: 75-79, 2000 (Pubitemid 30432567)
13. Davies J, Casey J, Li C, Crowe AV, McClelland P: Restoration of flow following haemodialysis catheter thrombus. Analysis of RT-PA infusion in tunneled dialysis catheters. J Clin Pharm Ther 29: 517-520, 2004 (Pubitemid 40007078)
14. Dowling K, Sansivero G, Stainken B, Siskin G, Dolen E, Ahn J, Mitchell N: The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters. Nephrol Nurs J 31: 199-200, 2004
15. Eyrich H, Walton T, Macon EJ, Howe A: Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis. Am J Health Syst Pharm 59: 1437-1440, 2002
16. Falk A, Samson W, Uribarri J, Vassalotti JA: Efficacy of reteplase in poorly functioning hemodialysis catheters. Clin Nephrol 61: 47-53, 2004 (Pubitemid 38100843)
17. Haymond J, Shalansky K, Jastrzebski J: Efficacy of low-dose alteplase for treatment of hemodialysis catheter occlusions. J Vasc Access 6: 76-82, 2005 (Pubitemid 41051846)
18. Hilleman DE, Dunlay RW, Packard KA: Reteplase for dysfunctional hemodialysis catheter clearance. Pharmacotherapy 23: 137-141, 2003
19. Hyman G, England M, Kibede S, Lee P, Willets G: The efficacy and safety of reteplase for thrombolysis of hemodialysis catheters at a community and academic regional medical center. Nephron Clin Pract 96: c39-c42, 2004 (Pubitemid 38456608)
20. Jacobs BR, Haygood M, Hingl J: Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. J Pediatr 139: 593-596, 2001 (Pubitemid 32977279)
21. Macrae JM, Loh G, Djurdjev O, Shalansky S, Werb R, Levin A, Kiaii M: Short and long alteplase dwells in dysfunctional hemodialysis catheters. Hemodial Int 9: 189-195, 2005 (Pubitemid 40932766)
22. Meers C, Toffelmire EB: Tissue plasminogen activator (T-PA) efficacy in the restoration of hemodialysis catheter function. CANNT J 9: 25-28, 1999
23. Nguyen TV, Dikun M: Establishing an alteplase dosing protocol for hemodialysis-catheter thrombosis. Am J Health Syst Pharm 61: 1922-1924, 2004 (Pubitemid 39481346)
24. Paulsen D, Reisoether A, Aasen M, Fauchald P: Use of tissue plasminogen activator for reopening of clotted dialysis catheters. Nephron 64: 468-470, 1993 (Pubitemid 23202861)
25. Zacharias JM, Weatherston CP, Spewak CR, Vercaigne LM: Alteplase versus urokinase for occluded hemodialysis catheters. Ann Pharmacother 37: 27-33, 2003
26. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E: TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B investigators. Circulation 98: 2805-2814, 1998
27. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J: A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 91: 3670-3674, 1994 (Pubitemid 24139493)
28. Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, Braunwald E: Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 40: 508-515, 2000
29. Tsikouris JP, Tsikouris AP: A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 21: 207-217, 2001
30. TNKase (tenecteplase) [prescribing information]. South San Francisco, CA, Genentech, Inc., 2008
31. Saxena AK, Panhotra BR: Haemodialysis catheter-related bloodstream infections: Current treatment options and strategies for prevention. Swiss Med Wkly 135: 127-138, 2005
32. Little MA, Walshe JJ: A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction. Am J Kidney Dis 39: 86-91, 2002